An interventional study of Screening, Brief Intervention, and Referral to Treatment (SBIRT) in Alcohol-Related Disorders, Substance-Related Disorders and Mental Health, sponsored by Emory University. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by Emory University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 107 studies in Alcohol-Related Disorders with a site in United States — 13 open to participants now, 18 under way, 1 of them phase 3. Alcohol-Related Disorders · United States.
Among the 107 studies in Alcohol-Related Disorders with a site in United States, this one is the 16th largest by planned enrollment of the 94 interventional ones that give a count, is one of 6 that started in 2025, is one of 48 with no phase, reaches primary completion later than 7 of the 17 other live ones, and was the 91st registered.
156 studies on the registry are indexed under Alcohol-Related Disorders; 23 are open to participants now.
Browse Alcohol-Related Disorders studies →13 of the 107 studies in Alcohol-Related Disorders with a site in United States are open now. Recruiting first, the newest first:
University of Pittsburgh · Sites in United States
Ages 14–18 · Healthy volunteers
University of Virginia · Sites in United States
Ages 18–44 · Women only · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 21–65
University of Maryland, Baltimore · Sites in United States
Ages 18–90
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Alcohol-Related Disorders studies recruiting now, 5 (31%) set no upper age limit and 7 (44%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 25 · Phase 3 5 · Phase 4 5
First in 1994; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 101 across 131 interventional studies indexed under Alcohol-Related Disorders.
Median enrollment 86 across the 94 interventional studies, 300 across the 13 observational. Of the 80 that completed or were terminated, 37 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 107 have an industry lead sponsor. The 10 most frequent:
Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.
Of its 238 completed or terminated interventional studies of FDA-regulated products, 179 (75%) have results posted.
Emory University has 1 study filed under Alcohol-Related Disorders — fewer than ten, so there is no comparison to draw.
7 of the studies in Alcohol-Related Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05807139National Institute on Drug Abuse (NIDA)Spironolactone in Alcohol Use Disorder (SAUD) | 2026-12-31 |
| NCT04391816National Institute on Alcohol Abuse and Alcoholism (NIAAA)COVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History Study | 2026-12-31 |
| NCT05910580Emory UniversityImproving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years | 2027-05-31 |
| NCT07053098University of Maryland, BaltimoreExternal Facilitation to Increase Prescribing of AUD Medications in the Psychiatric Setting | 2027-05-31 |
| NCT06444295University of WashingtonTesting the Impact of Thrive App Versions on Alcohol Use and Posttraumatic Stress After Recent Sexual Assault | 2027-07-15 |
Add all 7 to your calendar (.ics) → With an account.
Among the 107 studies in Alcohol-Related Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to test the effectiveness of evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) among adult patients who screen positive to one or more risky alcohol or substance use behaviors while seeking care at a sexual and reproductive health (SRH) clinic.
The main questions it aims to answer are:
Participants will receive in-person and telemedicine SBIRT, or usual care. Participants will complete surveys at interviews at baseline, 30 days, and 3 months.
Researchers will compare patients who received SBIRT to patients who receive usual care to see if patients who receive the SBIRT intervention have a greater reduction in negative outcomes as compared to those who receive usual care. In this setting, usual care consists of basic quantity and frequency questions asked inconsistently as part of the admission process and varying by provider, with no standardized approach to screening, treatment, follow-up, or referral.
Risky alcohol and drug use are associated with severe, negative, and long-term health outcomes and disparities, including sexual and reproductive health (SRH), among reproductive aged people in the United States. High rates and sequelae of alcohol and drug use disproportionately experienced by structurally marginalized groups shape lifelong health inequities for people of racial/ethnic minority, living in poverty, and residing in under-resourced and under-served communities. Among populations at risk of pregnancy-related sequelae (predominantly those self-identifying as women and thus this study's primary focus), harmful alcohol and substance use and alcohol use disorders (AUDs)/substance use disorders (SUDs) contribute to condom and contraceptive nonuse among those not intending pregnancy, sex while intoxicated, non-consensual sex, violence/rape, sexually transmitted infections, unintended pregnancy, and maternal and infant morbidity and mortality.
Family planning (FP) clinics are uniquely well-suited but entirely untapped sites for implementing and scaling integrated alcohol/substance use services. Largely community-based health centers that are publicly funded and/or serve Medicaid enrollees, FP clinics are a trusted care source and primary access point for reproductive aged women, and a safety net for the most socially disadvantaged groups. Yet few, if any, studies have rigorously evaluated interventions or implementation strategies to accelerate the uptake of alcohol/substance services in FP contexts. In obstetrics and HIV, widespread adoption of evidence-based SBIRT (screening, brief intervention, and referral to treatment) is precluded by multi-level barriers; data on specific challenges faced by FP providers are lacking. Virtually nothing is known about telemedicine, which has been rolled out for contraception and other routine visits during the pandemic, as a technological infrastructure for SBIRT. Whether and how the promising strategy of Implementation and Sustainment Facilitation (ISF) can bridge systems barriers and support scale up in FP settings is unknown.
The researchers of this study propose an explanatory, sequential, mixed methods study of alcohol and drug SBIRT in an expansive FP clinic network - a novel and highly impactful setting with a national reach of a diverse and largely structurally disadvantaged population of reproductive-aged women at greatest risk for AUDs/SUDs. The researchers will conduct a randomized Type 1 Hybrid Effectiveness-Implementation Trial within a large Northeastern regional affiliate and its four clinics of a national SRH care organization.
Results will inform an evidence-based, innovative, stakeholder-driven FP SBIRT model in response to the high-level calls for integrated women's health care. With concrete guidance for scaling alcohol/ drug services in SRH settings nationally, findings will promote women's health equity across the U.S.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients at study clinics who are randomized to receive the Screening, Brief Intervention, and Referral to Treatment (SBIRT) intervention, which is delivered in-person and through telemedicine.
Behavioral: Screening, Brief Intervention, and Referral to Treatment (SBIRT)
Patients at study clinics who are randomized to receive usual care. None of the clinic sites have implemented standardized screening, brief intervention, or referral to treatment components. In this setting, usual care consists of basic quantity and frequency questions asked inconsistently as part of the admission process and varying by provider, with no standardized approach to screening, treatment, follow-up, or referral.
Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based approach supported by national healthcare organizations, including the Preventative Services Task Force and the American College of Obstetrics and Gynecologists. Validated tools will efficiently screen an individual's substance use risk. Patients who screen in the risky/harmful range then receive a brief motivational interviewing-based intervention adapted from the evidence-based Brief Negotiated Interview, lasting 5-10 minutes, which provides feedback, helps explore health risks, and motivates change. Individuals who screen in the severe category, indicating a likely AUD/SUD, also receive a brief intervention, aimed at increasing motivation to accept a referral to treatment, and requiring a more intensive approach will also receive a warm-hand off referral to specialty addiction treatment. Procedures for SBIRT delivery will be adapted to the flow of telemedicine visits.
Average Number of Drinks Per Drinking Day
Participants are asked to self-report the number of drinks consumed on days when alcohol was consumed, during the past 30 days.
Time frame: Baseline, Day 30, Month 3
Number of Days of Drug Use
Participants are asked to self-report the number of days of drug use in the past 30 days.
Time frame: Baseline, Day 30, Month 3
Incidence of sex under influence of alcohol/drugs
Any incidence of sex under influence of alcohol/drugs in past 30 days.
Time frame: Baseline, Day 30, Month 3
Number of events of sex under influence of alcohol/drugs
The number of events of sex while under influence of alcohol/drugs in past 30 days.
Time frame: Baseline, Day 30, Month 3
Patient Health Questionnaire (PHQ-9)
The Patient Health Questionnaire (PHQ-9) is a 9-item instrument assessing symptoms of depression during the prior two weeks. Responses are given on a 4-point scale where 0 = not at all and 3 = nearly everyday. Total scores range from 0 to 27 where higher scores indicate greater feelings of depression. Scores of 0 to 4 indicate minimal depression, scores of 5 to 9 indicate mild depression, scores of 10 to 14 indicate moderate depression, scores of 15 to 19 indicate moderately severe depression, and scores of 20 or more indicate severe depression.
Time frame: Baseline, Day 30, Month 3
Number of Clinic Patients Receiving a Brief Intervention During Implementation Phase
The number of patients in each clinic who screen positive receiving a brief intervention during the implementation phase of the study.
Time frame: During the 12-month implementation phase
Number of Clinic Patients Receiving a Brief Intervention During Sustainment Phase
The number of patients in each clinic who screen positive who receive a brief intervention during the sustainment phase of the study.
Time frame: During the 12-month sustainment phase
Number of Providers Using SBIRT During Implementation Phase
The number of providers in each clinic using SBIRT during the implementation phase.
Time frame: During the 12-month implementation phase
Number of Clinics Using SBIRT During Sustainment Phase
The number of clinics using SBIRT during the sustainment phase.
Time frame: During the 12-month sustainment phase
Number of Providers Using SBIRT During Sustainment Phase
The number of providers in each clinic using SBIRT during the sustainment phase.
Time frame: During the 12-month sustainment phase
Number of Completed BIOS Tracking Sheets to Achieve Competency
The number of completed Brief Intervention Observation Sheets (BIOS) needed to achieve competency will be examined.
Time frame: During the preparation phase
Brief Intervention Observation Sheet (BIOS) Score
Fidelity to the intervention is assessed as the mean score on the first 10 items of the Brief Intervention Observation Sheet (BIOS). The score per provider is determined from a sample of audio recorded brief interventions. Responses to items are recorded as a "yes" or "no" assessment of whether the steps of the brief intervention were completed. The total score is the number of "yes" items and can range from 0 to 10, with higher scores indicating more steps completed.
Time frame: During the 12-month implementation phase
Brief Intervention Observation Sheet (BIOS) Score - Motivational Style
Fidelity to the intervention is assessed as the mean score on the 11th item of the Brief Intervention Observation Sheet (BIOS). The score per provider is determined from a sample of audio recorded brief interventions. Item 11 assesses the overall motivational interviewing style used by the provider. Scores are rated on a 7-point scale where 1 = not at all and 7 = very effectively. Higher scores indicate greater motivational interviewing style.
Time frame: During the 12-month implementation phase
Number of Days of Alcohol Use
Participants are asked to self-report the number of days they consumed alcohol during the past 30 days.
Time frame: Baseline, Day 30, Month 3
Number of Days of Binge Drinking
Participants are asked to self-report the number of days they consumed 4 or more alcoholic drinks per day during the past 30 days.
Time frame: Baseline, Day 30, Month 3
Alcohol Use Disorders Identification Test-Concise (AUDIT-C) Score
The Alcohol Use Disorders Identification Test-Concise (AUDIT-C) is a 3-item alcohol screening instrument that reliably identifies persons who are hazardous drinkers or have active alcohol use disorders (including alcohol abuse or dependence). The questionnaire asks about drinking behavior in the past 30 days. Responses to items are given on a 5-point scale where 0 = never and 4 = the highest frequency of alcohol use or consumption per drinking day. Total scores range from 0 (non-drinkers) to 12. Higher scores indicate that a person's alcohol consumption is likely to affect his or her health and safety.
Time frame: Baseline, Day 30, Month 3
Drug Abuse Screening Test (DAST-10) Score
The Drug Abuse Screening Test (DAST-10) is a 10-item instrument assessing drug use (not including alcohol and tobacco use). Each item is responded to as "yes" or "no" and the total score is the sum of all "yes" responses. Total scores range from 0 to 10 with a score of 0 indicating that no problems are reported and the degree of problems related to drug abuse increase as the total score increases. Scores of 1 or 2 indicate a low level of problems, scores of 3 to 5 indicate a moderate level of problems, scores of 6 to8 indicate substantial levels of problems, and scores of 9 and 10 indicate severe levels of problems related to drug abuse.
Time frame: Baseline, Day 30, Month 3
Incidence of condom nonuse
Participants are asked to report any incidence of condom nonuse monogamous encounters in the past 30 days, among women not intending pregnancy.
Time frame: Baseline, Day 30, Month 3
Number of events of condom nonuse
Participants reporting condom nonuse are asked to report the number of events of condom nonuse monogamous encounters in the past 30 days, among women not intending pregnancy.
Time frame: Baseline, Day 30, Month 3
Incidence of contraceptive nonuse
Participants are asked to report any incidence of contraceptive nonuse monogamous encounters in the past 30 days, among women not intending pregnancy.
Time frame: Baseline, Day 30, Month 3
Number of events of contraceptive nonuse
Participants reporting contraception nonuse are asked to report the number of events of contraceptive nonuse monogamous encounters in the past 30 days, among women not intending pregnancy.
Time frame: Baseline, Day 30, Month 3
Incidence of regretted/nonconsensual sex and sexual violence
Participants are asked to report any incidence of non-consensual sex, regretted sex, or sexual violence in past 30 days.
Time frame: Baseline, Day 30, Month 3
Number of events of regretted/nonconsensual sex and sexual violence
Participants reporting non-consensual sex, regretted sex, or sexual violence in past 30 days are asked to report the number of events.
Time frame: Baseline, Day 30, Month 3
Unintended pregnancy
Participants are asked to report any incidence of unintended pregnancy occurring in the past 30 days.
Time frame: Baseline, Day 30, Month 3
Generalized Anxiety Disorder 7-item (GAD-7) Scale Score
The Generalized Anxiety Disorder 7-item (GAD-7) instrument is a well-validated patient self-report scale measuring anxiety severity. Participants respond to statements to indicate how often they have been bothered by specified symptoms of anxiety (such as "feeling nervous, anxious, or on edge). Response choices include 0 = not at all sure, 1 = several days, 2 = over half the days, and 3 = nearly every day. Total scores range from 0 to 21 with higher scores indicating increased anxiety. A score of 0 to 4 indicates minimal anxiety, scores of 5 to 9 indicate mild anxiety, scores of 10 to 14 indicate moderate anxiety, and scores of 15 to 21 indicate severe anxiety.
Time frame: Baseline, Day 30, Month 3
World Health Organization-Five Well-Being Index (WHO-5) Score
The World Health Organization-Five Well-Being Index (WHO-5) a 5-item scale that measures subjective psychological well-being in past 14 days. Responses to items are given on a 6-point scale where 0 = at no time and 5 = all of the time. Total raw scores range from 0 to 25, with 0 representing the worst possible and 25 representing the best possible quality of life. Scores can also be multiplied by 4 to obtain a percentage score ranging from 0 to 100, where 0 represents the worst possible quality of life and 100 represents the best possible quality of life.
Time frame: Baseline, Day 30, Month 3
General Self-reported Health Score
Likert rating of general self-reported health in past 30 days
Time frame: Baseline, Day 30, Month 3
12-Item Short Form (SF-12) Health Survey Score
Quality of life is assessed with the SF-12 Health Survey. The SF-12 is a multipurpose, standardized self-report short form survey with 12 questions assessing mental and physical functioning. The SF-12 consists of 12 items with a Likert-type response format that measures quality of life with a Physical Component Summary (PCS) and Mental Component Summary (MCS). Subscales associated with the PCS include physical functioning, role limitations due to physical problems, bodily pain, and general health perceptions. Subscales associated with the MCS include vitality (energy and fatigue), social functioning, role limitations due to emotional problems, and mental health. A scoring algorithm is used to generate a total score for each component ranging from 0 to 100. Low values represent a poor health state while high values represent a good health state.
Time frame: Baseline, Day 30, Month 3
Number of Patients Screened During Implementation Phase
The number of patients, out of all patients seen at the study sites, who are screened during the implementation phase.
Time frame: During the 12-month implementation phase
Number of Patients Screened During Sustainment Phase
The number of patients, out of all patients seen at the study sites, who are screened during the sustainment phase.
Time frame: During the 12-month sustainment phase
Number of Patients Receiving Referral During Implementation Phase
The number of patients who screen at a severe level of alcohol use, who receive a referral during the implementation phase.
Time frame: During the 12-month implementation phase
Number of Patients Receiving Referral During Sustainment Phase
The number of patients who screen at a severe level of alcohol use, who receive a referral during the sustainment phase.
Time frame: During the 12-month sustainment phase
University of Missouri-Kansas City Screening & Brief Intervention Knowledge Assessment Score
SBIRT knowledge is assessed with the University of Missouri-Kansas City Screening \& Brief Intervention Knowledge Assessment. This instrument will be completed by providers undergoing training in SBIRT. Scores range from 0-20, with higher scores indicating more knowledge of SBIRT.
Time frame: During the implementation phase
Brief Intervention Observation Sheet (BIOS) Score During Preparation Phase
Fidelity to the intervention is assessed as the mean score on the first 10 items of the Brief Intervention Observation Sheet (BIOS), from the last observation conducted during provider training. The score per provider is determined from a sample of audio recorded brief interventions. Responses to items are recorded as a "yes" or "no" assessment of whether the steps of the brief intervention were completed. The total score is the number of "yes" items and can range from 0 to 10, with higher scores indicating more steps completed.
Time frame: During the preparation and implementation phases
Brief Intervention Observation Sheet (BIOS) Score - Motivational Style
Fidelity to the intervention is assessed as the mean score on the 11th item of the Brief Intervention Observation Sheet (BIOS), from the last observation conducted during provider training. The score per provider is determined from a sample of audio recorded brief interventions. Item 11 assesses the overall motivational interviewing style used by the provider. Scores are rated on a 7-point scale where 1 = not at all and 7 = very effectively. Higher scores indicate greater motivational interviewing style.
Time frame: During the preparation and implementation phases
Number of Participants with STI Diagnosis
The number of participants receiving a diagnosis of one more sexually transmitted infections (STIs) in past 30 days.
Time frame: Baseline, Day 30, Month 3
Past or current receipt of substance use treatment or services
Number of days/times the participant received treatment or counseling for alcohol or drugs or attended a self-help/mutual support meeting in past 30 days
Time frame: Baseline, Day 30, Month 3
Plan to share: Yes — Per the NIAAA Exemption Request Committee's determination electronic health records/administrative records data components will not be shared. Quantitative survey data will be shared.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: Data will be made available for sharing following publication of finding from this study and will be available indefinitely.
Access criteria: Anyone who wishes to access the data will be able to do so.
Started Jul 2025 (actual). Primary completion is estimated for May 2027, 22 months after the start.
Of 49 non-industry interventional studies with no phase under Alcohol-Related Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 44. This study's planned 22 months is below that.
Counting every sponsor, half of 49 studies reached it within 30 months; a quarter within 17 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.